Role of Phosphatidylinositol 3-Kinase Activation on Insulin Action and Its Alteration in Diabetic Conditions
-
- Asano Tomoichiro
- Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University
-
- Fujishiro Midori
- Department of Internal Medicine, Graduate School of Medicine, University of Tokyo
-
- Kushiyama Akifumi
- Department of Internal Medicine, Graduate School of Medicine, University of Tokyo
-
- Nakatsu Yusuke
- Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University
-
- Yoneda Masayasu
- Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University
-
- Kamata Hideaki
- Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University
-
- Sakoda Hideyuki
- Department of Internal Medicine, Graduate School of Medicine, University of Tokyo
この論文をさがす
説明
Inositol phospholipids phosphorylated on D3-position of their inositol rings (3-phosphoinositides) are known to play important roles in various cellular events. Activation of PI (phosphatidylinositol) 3-kinase is essential for aspects of insulin-induced glucose metabolism, including translocation of GLUT4 to the cell surface and glycogen synthesis. The enzyme exists as a heterodimer containing a regulatory subunit and one of two widely-distributed isoforms of the p110 catalytic subunit: p110α or p110β. Activation of PI 3-kinase and its downstream AKT has been demonstrated to be essential for almost all of the insulin-induced glucose and lipid metabolism such as glucose uptake, glycogen synthesis, suppression of glucose output and triglyceride synthesis as well as insulin-induced mitogenesis. Accumulated PI(3,4,5)P3 activates several serine/threonine kinases containing a PH (pleckstrin homology) domain, including Akt, atypical PKCs, p70S6 kinase and GSK.<br>In the obesity-induced insulin resistant condition, JNK and p70S6K are activated and phosphorylate IRS-proteins, which diminishes the insulin-induced tyrosine phosphorylation of IRS-proteins and thereby impairs the PI 3-kinase/AKT activations. Thus, the drugs which restore the impaired insulin-induced PI 3-kinase/AKT activation, for example, by suppressing JNK or p70S6K, PTEN or SHIP2, could be novel agents to treat diabetes mellitus.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 30 (9), 1610-1616, 2007
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679603902464
-
- NII論文ID
- 110006380237
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 8877655
-
- PubMed
- 17827708
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可